About Metsera
Metsera is a company based in New York (United States) founded in 2022 was acquired by Pfizer in September 2025. Metsera has raised $505 million across 2 funding rounds from investors including Fidelity Investments, Pfizer and T. Rowe Price. The company has 81 employees as of December 31, 2024. Metsera operates in a competitive market with competitors including Carmot, Zealand Pharma, Kailera, Viking Therapeutics and Zhejiang Daoer Biological Technology, among others.
- Headquarter New York, United States
- Employees 81 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Metsera, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$209.13 M (USD)-343.01as on Dec 31, 2024
-
EBITDA
-$134.39 M (USD)-229.52as on Dec 31, 2024
-
Total Equity Funding
$505 M (USD)
in 2 rounds
-
Latest Funding Round
$215 M (USD), Series B
Nov 12, 2024
-
Investors
Fidelity Investments
& 16 more
-
Employee Count
81
as on Dec 31, 2024
-
Acquired by
Pfizer
(Sep 22, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Metsera
Metsera is a publicly listed company on the NASDAQ with ticker symbol MTSR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Metsera
Metsera has successfully raised a total of $505M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $215 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Metsera
Metsera has secured backing from 17 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Pfizer and T. Rowe Price.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on tech sectors
|
Locked | Locked | Locked | |
|
Multiple sectors are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Private investment firm focused on multiple sectors
|
Locked | Locked | Locked |
Investor details for Metsera
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Metsera
Investment portfolio details for Metsera
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Metsera
Detailed financials for Metsera
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Metsera Comparisons
Peer comparison for Metsera
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Metsera
Metsera operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Carmot, Zealand Pharma, Kailera, Viking Therapeutics and Zhejiang Daoer Biological Technology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Disease-modifying therapies for metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Protein therapies for diabetes and gastrointestinal diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of therapies for treating obesity and related conditions
|
|
| Locked | Locked | Locked |
Small molecule therapies for endocrine and metabolic disorders are developed.
|
|
| Locked | Locked | Locked |
Protein therapies for metabolic diseases and cancers are developed.
|
Detailed competitors of Metsera
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Metsera
Complete news archive for Metsera
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Metsera
Metsera was founded in 2022 and raised its 1st funding round 2 years after it was founded.
Metsera is headquartered in New York, United States. It is registered at New York, New York, United States.
Clive Meanwell is the current CEO of Metsera.
Metsera is a funded company, having raised a total of $505M across 2 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Metsera is 81.
Metsera was founded in 2022 and is headquartered in New York, United States. Operations center on the biopharmaceutical sector, where a portfolio of treatments for obesity and metabolic diseases is advanced. New strategies are unlocked through scalable, sustainable, and personalized interventions aimed at weight loss, maintenance, and disease prevention. Focus remains on evidence-based approaches to address these health challenges.
Metsera's top competitors include Carmot, Zealand Pharma and Viking Therapeutics.
Yes, Metsera is publicly traded on NASDAQ under the ticker symbol MTSR.
Metsera has 17 investors. Key investors include Fidelity Investments, Pfizer, T. Rowe Price, Mubadala, and Janus Henderson Investors.
The ticker symbol of Metsera is MTSR on NASDAQ.